OnKure Therapeutics (NASDAQ:OKUR) Trading 4% Higher – Time to Buy?

OnKure Therapeutics (NASDAQ:OKUR)’s stock price traded up 4% during mid-day trading on Tuesday . The company traded as high as $9.38 and last traded at $8.60. 87,917 shares were traded during mid-day trading, an increase of 110% from the average session volume of 41,913 shares. The stock had previously closed at $8.27.

Analysts Set New Price Targets

Several research analysts have recently commented on OKUR shares. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of OnKure Therapeutics in a report on Friday, November 8th. Leerink Partnrs raised OnKure Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Oppenheimer began coverage on OnKure Therapeutics in a research note on Thursday, October 10th. They issued an “outperform” rating and a $35.00 target price for the company. Lifesci Capital upgraded shares of OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, October 10th. Finally, Leerink Partners assumed coverage on shares of OnKure Therapeutics in a research report on Thursday, December 5th. They issued an “outperform” rating and a $33.00 price objective for the company. Three investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, OnKure Therapeutics presently has a consensus rating of “Buy” and an average target price of $36.00.

OnKure Therapeutics Stock Up 4.0 %

The stock has a market capitalization of $28.75 million, a P/E ratio of -0.70 and a beta of 0.14. The company’s 50 day simple moving average is $13.98.

OnKure Therapeutics (NASDAQ:OKUR) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.13). Analysts forecast that OnKure Therapeutics will post -4.05 EPS for the current year.

About OnKure Therapeutics

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.